CJC-1295 (No DAC) + Ipamorelin
A combined product of two unapproved growth-hormone secretagogues; the pairing itself has never been tested in a controlled human trial.
What it is
This is the famous growth-hormone stack sold as a single combined product: a short-acting GHRH analog (CJC-1295 without DAC, essentially Mod GRF 1-29) plus the selective secretagogue ipamorelin.
The pairing logic is real pharmacology — two different receptors converging on GH release — and the outcome evidence is nonexistent: no controlled human trial has ever measured what this stack does to muscle, fat, recovery or sleep. Both components also share a shifting FDA compounding status since 2023.
What researchers have actually studied it for
GH release via two complementary receptors in component-level pharmacology; the combination's marketed outcomes have never been tested in trials.
How it works
CJC-1295 (no DAC) delivers a brief GHRH signal; ipamorelin pulses the ghrelin receptor. Hit both at once and the pituitary's GH release is amplified beyond either alone — a genuine synergy at the hormone-release level, marketed as if it were a synergy at the results level.
The molecule itself
A combined vial of Mod GRF 1-29 (the no-DAC GHRH analog) and the pentapeptide ipamorelin — two short-acting molecules chosen deliberately for pulse-mimicry, mixed in vendor-set ratios. The components' individual pharmacology is documented; the mixture's is assumed.
Where it came from
The no-DAC/ipamorelin pairing became the compounding world's flagship 'GH optimization' protocol in the 2010s — chosen over stronger secretagogues precisely for its short, pulse-mimicking profile. The combined vial is the retail evolution of that clinic protocol.
The timeline
2010s
Compounding clinics standardize the pairing as the flagship GH protocol.
late 2010s+
Combined single-vial products commodify it.
2023–24
Both components ride the Category 2 whipsaw; eligibility remains under review.
What the research record actually contains
- Component pharmacology: each raises GH in early human studies.
- The combination: no controlled trials on any clinical outcome, ever.
- Both components cycled on and off FDA's restricted compounding list (2023–2024) and remain under review.
What could change this assessment
Fully coupled to the 2026 compounding review of its components. Favorable eligibility would relegitimize the channel without adding a single outcome study — the distinction to keep in view.
What's known about risks
Short-term studies of each component reported tolerability; the stack's chronic use in healthy adults has never been safety-characterized. Sustained GH/IGF-1 elevation carries the same theoretical metabolic and proliferative questions as the rest of this category.
Where it stands legally
Unapproved as components and as a combination; compounding eligibility is a live, pharmacy-by-pharmacy question. Prohibited in tested sport.
Worth asking a licensed provider
- 1.What measurable outcome are we pursuing, and what human data connects this stack to it?
- 2.What is today's compounding status for both components at your pharmacy?
- 3.What monitoring — IGF-1, glucose — and what stop rules will we use?
Common claims, corrected
“The combined product is a designed pharmaceutical.”
Reality: It's a co-formulated compounding/gray product of two unapproved molecules; no combined-product trials or stability files exist publicly.
“Two mechanisms means twice the results.”
Reality: Two mechanisms means amplified GH pulses — documented — and zero outcome trials for what the amplification achieves, which is the part being sold.
CJC-1295 (No DAC) + Ipamorelin FAQ
What's the difference between this and CJC-1295 with DAC?
The no-DAC version acts for minutes-to-hours, preserving pulsatile GH release; the DAC version parks a signal for a week. The stack uses no-DAC on purpose — pulse mimicry is its selling point.
Does the CJC/ipamorelin stack build muscle?
No controlled human trial has measured muscle outcomes for the stack. It demonstrably raises GH pulses; everything after that is extrapolation.
Is this stack legal?
Neither component is FDA-approved; availability runs through compounding channels whose eligibility has flipped repeatedly since 2023. A licensed pharmacy holds today's answer.
Why no-DAC in the blend rather than DAC?
Pulse philosophy: short-acting components mimic natural GH rhythm, the pairing's entire physiological pitch — and a genuine design choice, unlike most of what surrounds it.
What should labs on this stack actually include?
Programs typically track IGF-1 (compliance proof); glucose and HbA1c have firmer safety logic given the GH axis's glycemic effects. What gets measured tells you what a program is really managing.